Keywords: AVEO Pharma, Johnson & Johnson, J&J, Centocor Ortho Biotech, License, RON-targetted antibodies, Anti-tumor activity
AVEO Pharma licenses RON-targeted antibodies to Johnson & Johnson unit for up to $555 million
Article | 01 June 2011
In a second significant deal this year, US cancer drug developer AVEO Pharmaceuticals (Nasdaq: AVEO) has entered into an exclusive ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
